Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Oct 20, 2025
- Pharmaceuticals
- R&D
Roche’s Announcement Regarding Vamikibart (Presentation of New Data in Noninfectious Uveitic Macular Edema)
TOKYO, October 20, 2025 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release on October 17, regarding vamikibart of the latest data from two global Phase III clinical trials (MEERKAT and SANDCAT) in noninfectious uveitic macular edema (UME), presented at the American Academy of Ophthalmology (AAO) 2025.
Please refer to the link below for details of the press release:
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp